Received: 28 February 2022 | Accepted: 4 March 2022

DOI: 10.1111/jcmm.17271

WILEY

CORRIGENDUM

In Xinhuai Dong et al,[1] the image data of flow cytometric analysis used as a blank control for 10 mg/kg rhVEGI-251-treated group, in the first panel of Figure 3A is incorrect. The correct figure is shown below. The authors confirm that all results and conclusions of this article remain unchanged.



FIGURE 3 rhVEGI-251 mediates the elimination of TAMs in tumour tissue. (A) Representative results of flow cytometric analysis of $CD11b^+$ $F4/80^+$ TAMs from $CD11b^+$ tumour-infiltrating mononuclear cells. The data in the first panel were used as a blank control group, and a symbol 'non' on the right of CD11b-PE-MACS means there were no CD11b MicroBeads added in this group. The data in the second panel represent the negative control group, and a symbol '–' on the right of CD11b-PE-MACS means these cells were collected as flow-through (wash fractions) after incubated with CD11b MicroBeads, which are CD11b microbeads negative selected cells. The purity of $CD11b^+$ cells among all selected cells is shown in the third panel. The proportions of $CD11b^+$ $F4/80^+$ cells are shown in the fourth panel. The images are representative of the results from three independent experiments. (B) The viability of purified TAMs was assessed by a trypan blue exclusion assay. (C) Statistical analysis of the percentage of $CD11b^+$ $F4/80^+$ TAMs among $CD11b^+$ tumour-infiltrating mononuclear cells. One-way ANOVA followed by Dunnett's multiple comparison test was performed, and significant differences are shown with asterisks (** indicates $p < 0.01$)

REFERENCE

1. Dong X, Huang X, Yao Z, et al. Tumour-associated macrophages as a novel target of VEGI-251 in cancer therapy. *J Cell Mol Med*. 2020;24(14):7884-7895. doi:10.1111/jcmm.15421